Vice President, Clinical Development, Oncology (AI)

Location: Onsite at hirify.global's headquarters in South San Francisco, California, United States. Travel of approximately 15–25% is expected for investigator and site engagement, scientific congresses, health authority meetings, and partner interactions.

Base salary: $350,000–$407,000 annually, plus bonus and equity.

Company

hirify.global is an AI-focused biotech startup developing generative AI models, computational biology platforms, and protein and antibody therapeutics for historically hard-to-drug targets.

What you will do

• Own integrated clinical development strategies for oncology programs from candidate selection through proof of concept and registrational development.
• Lead IND and CTA clinical strategy, first-in-human protocol design, dose escalation, dose optimization, and Phase 1 execution.
• Define translational, biomarker, patient-selection, companion diagnostic, and mechanism-of-action strategies.
• Guide transitions from dose expansion to late-stage and registrational development, including endpoints, comparators, populations, and accelerated approval strategies.
• Represent clinical development in interactions with FDA, EMA, and other health authorities while maintaining accountability for participant safety and GCP compliance.
• Build the clinical development function, including the team, operating model, governance, external network, CRO relationships, budget, and resource plan.

Requirements

• MD or MD/PhD required; medical oncology or hematology/oncology residency and fellowship with board certification strongly preferred.
• At least 12 years of clinical development experience in biotechnology or pharmaceuticals, including at least 5 years in a leadership role with program and direct-report accountability.
• Broad oncology experience across multiple tumor types, including dose-finding and dose-optimization studies in advanced cancer.
• Experience leading an oncology IND or CTA and the resulting first-in-human study through escalation, dose optimization, and expansion.
• Experience advancing an oncology program from Phase 1 into late-stage or registrational development, with strong biomarker and patient-selection expertise.
• Direct experience applying AI, machine learning, or advanced analytics to clinical development or translational questions, plus extensive FDA and preferably EMA regulatory experience.

Nice to have

• Experience with engineered proteins, antibodies, bispecific or multispecific antibodies, antibody–drug conjugates, targeted protein degraders, or cell and gene therapy.
• Companion diagnostic co-development and biomarker-defined indication approval experience.
• Experience with adaptive and model-informed drug development, seamless Phase 1/2 designs, digital pathology, digital endpoints, or real-world oncology data.
• Clinical leadership experience in an AI-native biotechnology or computational drug discovery company.

Culture & Benefits

• Open, flexible, and friendly work environment.
• Platform for long-term career development.
• Competitive compensation package including base salary, bonus, and equity.
• Commitment to diversity and inclusion.